Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by a deficiency of one of the enzymes involved in the degradation of glycosaminoglycans. Hearing loss is a common clinical presentation in MPS. This paper reviews the literature on hearing loss for each of the seven recognized subtypes of MPS. Hearing loss was found to be common in MPS I, II, III, IVA, VI, and VII, and absent from MPS IVB and MPS IX. MPS VI presents primarily with conductive hearing loss, while the other subtypes (MPS I, MPS II, MPS III, MPS IVA, and MPS VII) can present with any type of hearing loss (conductive, sensorineural, or mixed hearing loss). The sensorineural component develops as the disease progresses, but there is no consensus on the etiology of the sensorineural component. Enzyme replacement therapy (ERT) is the most common therapy utilized for MPS, but the effects of ERT on hearing function have been inconclusive. This review highlights a need for more comprehensive and multidisciplinary research on hearing function that includes behavioral testing, objective testing, and temporal bone imaging. This information would allow for better understanding of the progression and etiology of hearing loss. Owing to the prevalence of hearing loss in MPS, early diagnosis of hearing loss and annual comprehensive audiological evaluations are recommended.
7 March 2024 in American Journal of Speech-Language Pathology
Purpose: Rehabilitation intervention descriptions often do not explicitly identify active ingredients or how those ingredients lead to changes in patient functioning. The Rehabilitation Treatment Specification System (RTSS) provides guidance to identify the critical aspects of any rehabilitation therapy and supported the development of standardly named ingredients and targets in voice therapy (Rehabilitation Treatment Specification System for Voice Therapy [RTSS-Voice]). This study sought to test the content validity of the RTSS-Voice and determine if the RTSS-Voice can be used to identify commonalities and differences in treatment (criterion validity) across clinicians in everyday clinical practice. Method: Five speech-language pathologists from different institutions videotaped one therapy session for 59 patients diagnosed with a voice or upper airway disorder. Specifications were created for each video, and iterative rounds of revisions were completed with the treating clinician and two RTSS experts until consensus was reached on each specification. Results: All 59 sessions were specified without the addition of any targets or ingredients. There were two frequent targets: (a) increased volition and (b) decreased strained voice quality. There were three frequent ingredients: (a) information regarding the patient's capability and motivation to perform a therapeutic behavior, (b) knowledge of results feedback, and (c) opportunities to practice voicing with improved resonance and mean airflow. Across sessions treating vocal hyperfunction, there was large variability across clinicians regarding the types and number of treatment components introduced, types of feedback provided, and vocal practice within spontaneous speech and negative practice. Conclusions: The RTSS and the RTSS-Voice demonstrated strong content validity, as they comprehensively characterized 59 therapy sessions. They also demonstrated strong criterion validity, as commonalities and differences were identified in everyday voice therapy for vocal hyperfunction across multiple clinicians. Future work to translate RTSS principles and RTSS-Voice terms into clinical documentation can help to understand how clinician and patient variability impacts outcomes and bridge the research–practice gap. Supplemental Material: https://doi.org/10.23641/asha.24796875
10 July 2025 in American Journal of Speech-Language Pathology
Purpose: The purpose of this study was to examine transfeminine individuals' goals for gender-affirming voice care and what they consider success in gender-affirming voice therapy. Method: Fifteen transfeminine individuals completed semistructured interviews prior to commencement of gender-affirming voice care. Interviews explored individuals' voice goals, expectations for treatment, and desired treatment outcomes. Interviews were transcribed and analyzed by four speech-language pathologists with experience in gender-affirming voice using a grounded theory approach. Line-by-line, open, and axial coding were conducted to identify themes and subthemes. Results: Four dominant themes and 12 subthemes were identified from the interviews. Dominant themes included the following: (a) Individuals hope that voice therapy will reduce adverse voice-related experiences, (b) individuals expect successful voice therapy to facilitate specific voice goals, (c) individuals expect successful voice therapy to facilitate communication across varying contexts, and (d) individuals want specific guidance in voice therapy. Past adverse experiences included being misgendered or feeling isolated due to vocal function. Specific voice goals included having a voice that was perceived as more feminine, higher in pitch, and produced with less mental and phonatory effort. Participants hoped that success in voice therapy would facilitate occupational voice use, phone use, and interactions with strangers. They also expressed a desire for specific strategies or exercises to achieve desired voice changes. Conclusions: Transfeminine individuals seeking gender-affirming voice training have specific goals and expectations for voice therapy, which are driven by past experiences, interactional partners, and communicative context. Future study should continue to clarify the manner in which patient experiences drive voice outcomes in this population.